

# **Cobra-PLA provides higher oropharyngeal leak pressure than LMA-Classic and LMA-Unique** A meta-analysis with 22 studies

Yuan Tan, MD, Guangyou Duan, PhD, Qin Chen, MD, Feng Chen, MD, Hong Li, PhD $^{st}$ 

#### Abstract

Cobra Perilaryngeal Airway (Cobra-PLA) is a relatively new single-use supraglottic device employed during general anesthesia. This meta-analysis includes randomized controlled trials (RCTs) yielding extensive comparison results among Cobra-PLA, Laryngeal Mask Airway (LMA)-Classic, and LMA-Unique.

Two authors performed searches in EMBASE, CENTRAL, PubMed, and ScienceDirect to identify RCTs that compared Cobra-PLA with LMA-Classic and with LMA-Unique in patients undergoing general anesthesia. Both random- and fixed-effects models were used. Begg's funnel plot was used to evaluate publication bias.

Twenty-two RCTs with a total of 1845 patients were included. Cobra-PLA offered significantly higher oropharyngeal leak pressure than LMA-Classic [mean difference (MD) = 3.56 (1.56, 5.55), P = .0005] and LMA-Unique [MD = 4.44 (2.12, 6.76), P = .0002]. First-insertion success rate, ease of insertion, insertion time, and reported complications among Cobra-PLA, LMA-Classic, and LMA-Unique were similar.

Compared with the commonly used LMA-Classic and LMA-Unique, Cobra-PLA provides superior airway sealing.

**Abbreviations:** Cobra-PLA = Cobra-Perilaryngeal Airway, LMA = Laryngeal Mask Airway, MD = mean differences, NMB = neuromuscular blocker, OLP = oropharyngeal leak pressure, RCT = randomized controlled trial, RR = relative ratio.

Keywords: Cobra perilaryngeal airway, laryngeal mask airway, supraglottic devise

# 1. Introduction

Since its inception by Archie Brain in 1981, the Classic Laryngeal Mask Airway (LMA) have shown unexpectedly high popularity among anesthetists.<sup>[1,2]</sup> In the past decades, new airway devices, such as Cobra Perilaryngeal Airway (PLA) and LMA-Unique, have been fabricated by modifying the LMA-Classic.

Cobra-PLA contains a polycarbonate transparent breathing tube, a high volume low-pressure cuff, and a far end cobrashaped head. The soft pointed end of the cobra head is devised to provide passage of the device into the hypopharynx via crooking in the direction of the glottis. At the time of insertion, the distal head keeps the throat soft tissue and the epiglottis in place and connects to the throat inlet, allowing spontaneous or controlled breathing through the slotted opening.<sup>[3]</sup>

Editor: Chien-Kun Ting.

The authors have no conflicts of interest to disclose.

Department of Anesthesiology, Xinqiao Hospital of Army Military Medical University, Shapingba District, Chongqing, China.

<sup>\*</sup> Correspondence: Hong Li, department of Anesthesiology, Xinqiao Hospital of Army Military Medical University, 83 Xinqiaozhengjie, Shapingba District, 40000, Chongqing, China (e-mail: Ih78553@126.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2019) 98:26(e15832)

Received: 11 October 2018 / Received in final form: 20 March 2019 / Accepted: 3 May 2019

http://dx.doi.org/10.1097/MD.000000000015832

Oropharyngeal leak pressure (OLP) is used to quantify the efficacy of airway sealing in devices and indicates airway protection, successful placement, and positive pressure ventilation.<sup>[4,5]</sup> Several randomized controlled trials (RCTs) compared Cobra-PLA with LMA-Classic and LMA-Unique. Four RCTs<sup>[6–8]</sup> found higher OLP values in Cobra-PLA compared with LMA-Classic, whereas 3 other studies<sup>[2,9–10]</sup> found no difference. Comparison with LMA-Unique also provides contested results across studies. Therefore, RCTs alone cannot sufficiently provide a clear evaluation of the Cobra-PLA.

To solve this problem, we conducted a meta-analysis including 22 RCTs that compared the supraglottic devices during general anesthesia. OLP was the primary outcome, and rate of first-insertion success, ease of airway insertion, insertion time, and reported complications associated with the device were the secondary outcomes. And furthermore, subgroups analysis were performed considering confounding factors, such as age, surgery type, neuromuscular blocker (NMB) use, and the possible effect of the measurement method on the OLP.

# 2. Materials and methods

This meta-analysis was performed based upon the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.<sup>[11]</sup>

#### 2.1. Literrature search

Electronic databases EMBASE, CENTRAL, and PubMed, as well the ScienceDirect, were searched for eligible studies. All researches were conducted in May 2018. The search items were as follows:

- (ii) Laryngeal Mask Airway Classic (CLMA), LMA-Classic, Laryngeal Mask Airway-Unique (LMAU), or LMA-Unique; and
- (iii) randomized controlled trial, randomly, or randomized. The key words were linked using "AND" (for "Cobra-PLA," "LMA Classic," and "randomized") and "OR" (for "Cobra Perilaryngeal Airway," "Cobra-PLA," and "CPLA").

The search was performed across English language content.

#### 2.2. Study selection

We included only published prospective RCTs comparing Cobra-PLA with other 2 LMAs during general anesthesia. The exclusion criteria included correspondence, case reports, reviews, animal studies, and non-English papers.

#### 2.3. Data collection

The following data were collected: name of the first author, publication year, age, patients' number, surgical type, premedication, neuromuscular blocker use, type of ventilation, OLP and its measurement method, the rate of first-insertion success, insertion ease, insertion time, and complications associated with the devices (sore throat, laryngospasm, dysphagia, bloodsoiled device, or other rare complications). Two independent authors gathered the data. Disagreements were resolved by discussion.

# 2.4. Risk of bias assessment

Cochrane Collaboration standards were used to evaluate the risk of bias in RCTs. The standards were as follows: randomization, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias. A judgment of high, unclear, or low risk of material bias was assigned for each item.

#### 2.5. Statistical analysis

Review Manger 5.3 software was used to count data. Weighted mean differences (MD), relative ratio (RR), and associated 95% confidence intervals were applied to pool data. An  $I^2 > 50\%$  denotes heterogeneity, and the random-effects model was used. Sensitivity analysis was used to search for possible explanations for significant heterogeneity. Subgroups were analyzed considering confounding factors, such as age, surgery type, NMB use, and the possible effect of the measurement method on the OLP.

If 1 trial contained more than 1 intervention group, each group was regarded as a study. Publication bias of eligible studies was tested by visual inspection of funnel plots (if the number exceeded 10).

#### 3. Results

Figure 1 described detailed steps and study selection. Electronic database search revealed that 15 trials where Cobra-PLA was compared with LMA-Classic<sup>[2,6-10,12-15,16-19]</sup> and 8 trials containing a comparison between Cobra-PLA and LMA-




Table 1

| Author/Year                     | Age, yr | Group                   | Number   | Surgery                         | Premedication        | NMB                    | Ventilation  | OLP measurement method |
|---------------------------------|---------|-------------------------|----------|---------------------------------|----------------------|------------------------|--------------|------------------------|
| Gaitini <sup>[27]</sup>         | adult   | Cobra-PLA               | 25       | Not reported                    | No                   | Vecuronium 0.1 mg/kg   | Controlled   | Manometric stability   |
| 2003                            |         | LMA-Unique              | 25       |                                 |                      |                        |              |                        |
| Akcao <sup>[17]</sup>           | >18     | Cobra-PLA               | 40       | Orthopedic, gynecologic,        | Midazolam 1–2 mg     | No                     | Spontaneous  | oral capnography       |
| 2004                            |         | LMA-Classic             | 41       | and general surgery             |                      |                        |              |                        |
| Turan <sup>[19]</sup>           | >18     | Cobra-PLA               | 30       | Minor gynaecological            | Yes                  | mivacurium 0.2mg/kg    | Controlled   | Not checked            |
| 2006                            |         | LMA-Classic             | 30       | and general surgery             |                      |                        |              |                        |
| Van <sup>[26]</sup>             | 18–80   | Cobra-PLA               | 106      | Elective surgery                | 10 mg diazepam       | No                     | Controlled   | Manometric stability   |
| 2006                            |         | LMA-Unique              | 106      |                                 |                      |                        |              |                        |
| Van <sup>[21]</sup>             | 18–80   | Cobra-PLA               | 95       | Elective surgery                | No                   | No                     | Spontaneous  | Not checked            |
| 2006                            |         | LMA-Unique              | 96       |                                 |                      |                        |              |                        |
| Gaitini <sup>[22]</sup>         | >18     | Cobra-PLA               | 40       | Minor routine surgery           | No                   | No                     | Spontaneous  | Manometric stability   |
| 2006                            |         | LMA-Unique              | 40       |                                 |                      |                        |              |                        |
| Agah, <sup>[13]</sup>           | 6-70    | Cobra-PLA               | 100      | Ophthalmic surgery              | No                   | Atracurium 0.5 mg/kg   | Controlled   | Audible noise          |
| 2006                            |         | LMA-Classic             | 100      |                                 |                      |                        |              |                        |
| Galvin <sup>[6]</sup>           | 24–38   | Cobra-PLA               | 20       | Gynecological laparoscopy       | No                   | No                     | Controlled   | Audible noise          |
| 2007                            |         | LMA-Classic             | 20       |                                 | N.                   | D                      | 0            | NULL IN THE I          |
| Nam <sup>[18]</sup>             | adult   | Cobra-PLA               | 19       | Orthopaedic surgery of the knee | No                   | Rocuronium 0.6 mg/kg   | Controlled   | Not checked            |
| 2007                            | 0.40    | LMA-Classic             | 19       | Et all'an anna a                | N.                   |                        | 0            | NULL IN THE I          |
| Kaya <sup>[20]</sup>            | 6–13    | Cobra-PLA               | 30       | Elective surgery                | No                   | mivacurium 0.2 mg/kg   | Controlled   | Not checked            |
| 2008                            | 10      | LMA-Classic             | 30       | Florit a second second          | M. I                 | N.                     | 0            | NA                     |
| Szmuk <sup>[23]</sup>           | <12     | Cobra-PLA               | 100      | Elective procedures             | Midazolam, 0.5 mg/kg | No                     | Spontaneous  | Manometric stability   |
| 2008<br>Gaitini <sup>[24]</sup> | .0      | LMA- Unique             | 100      |                                 | Ne                   |                        | Operatural   |                        |
|                                 | <8      | Cobra-PLA               | 40       | Elective general surgery        | No                   | Rocuronium 0.4 mg/kg   | Controlled   | Audible noise          |
| 2008<br>Khazin <sup>[10]</sup>  | 10 65   | LMA-Unique<br>Cobra-PLA | 34<br>30 | Floative ourgany                | Protizalam 0.05 mg   | Decuracium 0.6 mg/kg   | Controllad   | Audible pains          |
| 2008                            | 18–65   | LMA-Classic             | 30<br>30 | Elective surgery                | Brotizolam 0.25 mg   | Rocuronium 0.6 mg/kg   | Controlled   | Audible noise          |
| Strydom <sup>[14]</sup>         | >18     | Cobra-PLA               | 30<br>20 | Elective peripheral surgery     | No                   | No                     | Spontaneous  | Not checked            |
| 2008                            | >10     | LMA-Classic             | 20<br>25 | Elective periprieral surgery    | NU                   | NU                     | Spontaneous  | NUL CHECKEU            |
| Andrews <sup>[3]</sup>          | >18     | Cobra-PLA               | 49       | Elective surgery                | No                   | No                     | Spontaneous  | Audible noise          |
| 2009                            | 210     | LMA-Classic             | 41       | Elective surgery                | NO                   | NO                     | opontaricous |                        |
| Schebesta <sup>[8]</sup>        | 18-85   | Cobra-PLA               | 30       | Routine surgical procedures     | No                   | No                     | Controlled   | Audible noise          |
| 2010                            | 10 00   | LMA-Classic             | 30       | riodane surgical procedures     | 110                  | 110                    | Controlled   |                        |
| Van <sup>[2]</sup>              | <16     | Cobra-PLA               | 35       | Elective surgery                | No                   | No                     | Spontaneous  | Audible noise          |
| 2012                            | 1.0     | LMA-Classic             | 31       | Liooard bargery                 | 110                  | 110                    | opontanoodo  |                        |
| 2012                            |         | LMA-Unique              | 31       |                                 |                      |                        |              |                        |
| Karabiyik <sup>[16]</sup>       | 18–68   | Cobra-PLA               | 15       | Ophthalmic surgery              | No                   | Rocuronium 0.6 mg/kg   | Controlled   | Not checked            |
| 2012                            | 10 00   | LMA-Classic             | 15       | oprialarito ourgory             | 110                  | noodronidin oro nigrig | Controllou   |                        |
| Ratajczyk <sup>[15]</sup>       | 26-65   | Cobra-PLA               | 30       | Elective surgery                | No                   | No                     | Controlled   | Not reported           |
| 2013                            | 00      | LMA-Classic             | 30       |                                 |                      |                        |              |                        |
| Schebesta <sup>[25]</sup>       | 18-85   | Cobra-PLA               | 10       | Routine gynaecological          | No                   | No                     | Controlled   | Not checked            |
| 2014                            |         | LMA-Unique              | 8        | procedures                      |                      |                        |              |                        |
| Peker <sup>[11]</sup>           | 1–10    | Cobra-PLA               | 15       | Extra-ocular ophthalmic         | Midazolam 0.3 mg/kg  | No                     | Controlled   | Audible noise          |
| 2015                            |         | LMA-Classic             | 15       | surgery                         | 5 5                  |                        |              |                        |
| Yaghoobi <sup>[9]</sup>         | >18     | Cobra-PLA               | 37       | Surgery of the obese patients   | No                   | Atracurium 0.5 mg/kg   | Controlled   | Manometric stability   |
| 2015                            |         | LMA-Classic             | 36       |                                 |                      | 5 0                    |              | -                      |

Cobra-PLA = Perilaryngeal Airway, LMA = Laryngeal Mask Airway, NMB = Neuromuscular blocker, OLP = Oropharyngeal leak pressure.

Unique.<sup>[2,20–26]</sup> The characteristics and methodological quality of RCTs are shown in Tables 1 and 2, respectively.

#### 3.1. Cobra-PLA versus LMA-Classic

**3.1.1. OLP.** A pooled analysis of data from 8 trials<sup>[2–3,6,7–10,16]</sup> revealed that Cobra-PLA provided significantly higher OLP than LMA-Classic [MD=3.56 (1.56, 5.55),  $I^2$ =88%, P=.0005] (Fig. 2). Sensitivity analysis certified that the pooled outcome was not changed by a single study. Given substantial heterogeneity, we used subgroup analysis to determine the impact of confounding factors (Table 3). On the basis of age subgroup analysis, the pooled results showed that Cobra-PLA provided slightly higher OLP in the child subgroup despite the lack of significant difference [MD=2.36 (-0.02, 4.74),  $I^2$ =0%, P=.05] and higher OLP in the adult subgroup [MD=3.90 (1.56, 6.23),  $I^2$ =91%, P=.001] compared with LMA-Classic. Five trials<sup>[2–3,7,10,15–16]</sup> that did not use NMB were included, and the combinative result was higher for Cobra-PLA than for LMA-

Classic [MD = 3.92 (2.77, 5.07),  $I^2 = 0\%$ , P < .0001]. With NMB, the combinative result was not significantly different between the 2 groups [MD = 2.95 (-2.74, 8.63),  $I^2 = 98\%$ , P = .31]. When the pooled analysis was restricted to the subgroup analysis of surgery type, Cobra-PLA also provided higher OLP than LMA-Classic in non-laparoscopic surgery [MD = 3.41 (1.25, 5.57),  $I^2 = 90\%$ , P = .002]. Data on laparoscopic surgery in only 1 trial<sup>[6]</sup> were not counted. Studies<sup>[2-3,6,7,9-10]</sup> using the measurement of audible noise found that Cobra-PLA exhibited comparatively high OLP [MD = 2.70 (0.86, 4.54),  $I^2 = 65\%$ , P = .004].

**3.1.2.** Rate of first-insertion success, insertion ease, and insertion time. Thirteen trials<sup>[2-3,6,7-8,10,14-19]</sup> examined the rate of insertion success at the first attempt and found no significant difference between the 2 devices [RR=1.03 (0.95, 1.12),  $I^2$  = 62%, P=.45]. Heterogeneity was significantly decreased ( $I^2$  = 0%, P=.10) upon the removal of 5 studies<sup>[8,15,17-19]</sup> that used NMB. The funnel plot of first-insertion success rate did not

# Table 2

| Risk of bias assessment for eva | luation the quality of | each included trials. |
|---------------------------------|------------------------|-----------------------|
|---------------------------------|------------------------|-----------------------|

| Study (author,<br>year)        | Random sequence<br>generation | Allocation con<br>cealment | Blingding of participant<br>and personnel | Blingding of outcome<br>assessment | Incomplete<br>outcome data | Selective reporting | Other<br>bias |
|--------------------------------|-------------------------------|----------------------------|---|------------------------------------|----------------------------|---------------------|---------------|
| Gaitini 2003 <sup>[27]</sup>   | Low                           | Unclear                    | Low                                       | Unclear                            | Unclear                    | Unclear             | Unclear       |
| Akcao 2004 <sup>[17]</sup>     | Low                           | Low                        | high                                      | Low                                | Low                        | Low                 | Low           |
| Turan 2006 <sup>[19]</sup>     | Low                           | Low                        | Low                                       | high                               | Low                        | Low                 | Low           |
| Van Z 2006 <sup>[26]</sup>     | Low                           | Low                        | Unclear                                   | high                               | Low                        | Low                 | Low           |
| Van 2006 <sup>[21]</sup>       | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Gaitini 2006 <sup>[22]</sup>   | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Agah 2006 <sup>[13]</sup>      | Low                           | Unclear                    | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Galvin 2007 <sup>[16]</sup>    | Low                           | Unclear                    | Low                                       | Low                                | Low                        | Low                 | Low           |
| Nam 2007 <sup>[18]</sup>       | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Kaya 2008 <sup>[20]</sup>      | Low                           | Low                        | high                                      | Low                                | Low                        | Low                 | Low           |
| Szmuk 2008 <sup>[23]</sup>     | Low                           | Low                        | Unclear                                   | Low                                | Low                        | Low                 | Low           |
| Gaitini 2008 <sup>[24]</sup>   | Low                           | Low                        | Low                                       | Low                                | Low                        | Low                 | Low           |
| Strydom 2008 <sup>[14]</sup>   | Low                           | Low                        | Low                                       | Unclear                            | Low                        | Low                 | Low           |
| Khazin 2008 <sup>[10]</sup>    | Low                           | Unclear                    | Unclear                                   | Low                                | Low                        | Low                 | Low           |
| Andrews 2009 <sup>[3]</sup>    | Low                           | Unclear                    | Low                                       | Low                                | Low                        | Low                 | Low           |
| Schebesta 2010 <sup>[8]</sup>  | Low                           | Low                        | Low                                       | Unclear                            | Low                        | Low                 | Low           |
| Van 2012 <sup>[2]</sup>        | Low                           | Low                        | Low                                       | Low                                | Low                        | Low                 | Low           |
| Karabiyik 2012 <sup>[16]</sup> | Low                           | Unclear                    | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Ratajczyk 2013 <sup>[15]</sup> | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Schebesta 2014 <sup>[25]</sup> | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Yaghoobi 2015 <sup>[9]</sup>   | Low                           | Low                        | Unclear                                   | Unclear                            | Low                        | Low                 | Low           |
| Peker 2015 <sup>[11]</sup>     | Low                           | Unclear                    | Low                                       | Low                                | Low                        | Low                 | Low           |

indicate evident substantial asymmetry (Fig. 3). Insertion ease and insertion time were similar between the 2 devices [RR = 1.10 (0.95, 1.27),  $I^2$  = 30%, P = .22; MD = 2.80 (-0.68, 6.28),  $I^2$  = 71%, P = .11, respectively]. When we removed individual studies, the heterogeneity of insertion ease and insertion time was not markedly decreased. Figure 2 lists the forest plot of this analysis.

**3.1.3.** Complications. The incidence of reported complications was assessed: blood staining on the device was reported in 10 studies,  $^{[2,6,8,12-16,18-19]}$  sore throat was found in 7 studies,  $^{[3,6,8,12,14,16,18]}$  and laryngospasm was observed in 5 studies.  $^{[6,9,14,16,19]}$  The 2 groups exhibited a similar incidence of blood staining, sore throat, and laryngospasm [RR=1.45 (0.75, 2.80),  $I^2$ =78%, P=.27; RR=0.90 (0.65, 1.26),  $I^2$ =56%, P=.54; RR=1.01 (0.24, 4.22),  $I^2$ =0%, P=.99, respectively] (Fig. 4). The funnel plot of blood staining indicated possible asymmetry (Fig. 3). None of the serious complications were reported in any included studies.

# 3.2. Cobra-PLA versus LMA-Unique

**3.2.1. OLP.** A combined result from 6 trials<sup>[2,17–19,25–26]</sup> demonstrated that Cobra-PLA offered significantly higher OLP than LMA-Unique [MD = 4.44 (2.12, 6.76),  $I^2 = 91\%$ , P = .0002] (Fig. 4). Based on age subgroup analysis, the pooled results showed that Cobra-PLA provided higher OLP in child and adult subgroups than LMA-Unique [MD = 2.79 (0.25, 5.34),  $I^2 = 89\%$ , P = .03; MD = 7.85 (3.44, 12.26),  $I^2 = 90\%$ , P = .0005, respectively]. Regardless of the presence or absence of NMB during anesthesia induction, pooled data showed that Cobra-PLA presented higher OLP compared with LMA-Unique [MD = 9.45 (2.76, 16.14),  $I^2 = 93\%$ , P = .006; MD = 3.05 (0.95, 5.16),  $I^2 = 85\%$ , P = .004, respectively]. All trials involved non-laparoscopic surgery. Four trials<sup>[15,18,25,26]</sup> measured manometric stability, and Cobra-PLA yielded higher combined result in

comparison with LMA-Unique [MD=4.73 (1.90, 7.56),  $I^2 = 92\%$ , P = .001]. However, the result was not significantly different between the 2 groups [MD=3.42 (-2.32, 9.16),  $I^2 = 90\%$ , P = .24] (Table 4) when audible noise measurement was used.

3.2.2. First-insertion success rate, insertion ease, and insertion time. Six studies<sup>[2,17,18,20,25-26]</sup> investigated the insertion success rate at the first attempt, and no significant difference was observed between the 2 devices [RR=0.98 (0.94, 1.02),  $I^2$ =0%, P=.31]. Ease of insertion is similar between 2 devices [RR=0.94 (0.73, 1.22),  $I^2$ =87%, P=.67]. Insertion time is also similar [MD=0.37 (-1.35, 2.08),  $I^2$ =67%, P=.68]. Figure 5 lists the forest plot of these analyses.

**3.2.3.** Complications. The incidence of reported complications was assessed: blood staining on the device, sore throat, and laryngospasm were reported in 4,<sup>[2,21-23]</sup> 4,<sup>[2,21-22,26]</sup> and 3 studies,<sup>[2,22-23]</sup> respectively. The 2 groups showed similar incidence of blood staining, sore throat, and laryngospasm [RR=0.71 (0.42, 1.20),  $I^2$ =26%, P=.20; RR=1.10 (0.76, 1.60),  $I^2$ =0%, P=.60; RR=0.49 (0.12, 1.95),  $I^2$ =0%, P=.31, respectively] (Fig. 6). None of the serious complications were reported in any of the included studies.

# 4. Discussion

The main finding of the present meta-analysis is that Cobra-PLA offers significantly higher OLP than LMA-Classic and LMA-Unique undergoing general anesthesia. First-insertion success rate, ease of insertion, insertion time, and reported complications were similar among 3 devices.

Airway sealing pressure or airway leak pressure is also referred to OLP, which is the most important indicator for assessing the safety and efficacy of airway devices.<sup>[27]</sup> OLP decides the practicability of degree of airway protection and safe positive

|   |   | ra-PLA  |  |   | Class   |   |  | Mean Difference   |  | Mean Difference  |   |
|---|---|---|--|---|---|---|--|---|--|--|---|
| Study or Subgroup   | Mean  | SD T  | otal N   | lean  | SD  | Total   | Weight   | IV, Random, 95% Cl  |  | IV, Random, 95% Cl   |   |
| Akca 2004   | 23  | 6   | 40   | 18  | 5   | 41  | 12.9%  | 5.00 [2.59, 7.41]   | 1  |  |   |
| Andrews 2009  | 22  | 9   | 49   | 18  | 6   | 40  | 11.5%  | 4.00 [0.87, 7.13]   | È.   |  |   |
| Galvin 2007   | 25.2  | 7.9   | 20   | 20.3  | 4.9   | 20  | 9.6%   | 4.90 [0.83, 8.97]   |  |  |   |
| Khazin 2008   | 26  | 3   | 30   | 26  | 3   | 30  | 14.6%  | 0.00 [-1.52, 1.52]  |  |  |   |
| Peker 2015  | 25.1  | 5.4   | 15   | 22.4  | 3.7   | 15  | 11.1%  |   |  |  |   |
|   |   |   |  |   |   |   |  | 2.70 [-0.61, 6.01]  |  |  |   |
| Schebesta 2010  | 24  | 4   | 30   | 20  | 4   | 30  | 13.7%  | 4.00 [1.98, 6.02]   |  |  |   |
| /an 2012  | 28.4  | 7.2   | 35   | 26.4  | 7   | 31  | 10.8%  | 2.00 [-1.43, 5.43]  |  |  |   |
| (aghoobi 2015   | 24.8  | 0.9   | 37   | 19  | 1   | 36  | 15.8%  | 5.80 [5.36, 6.24]   |  | •  |   |
| otal (95% CI)   |   |   | 256  |   |   | 243   | 100.0%   | 3.56 [1.56, 5.55]   | Ě  | •  |   |
| Heterogeneity: Tau <sup>2</sup> =   | = 6.52; C   | hi <sup>2</sup> = 59.   | 80, df=  | = 7 (P  | < 0.00  | 001); F   | = 88%  |   | -  |  | _ |
| Fest for overall effect:  |   |   |  |   |   |   |  |   | -20  | -10 0 10   | 2 |
|   |   |   |  |   |   |   |  |   |  | Favours [LMA-classic] Favours [Cobra-PLA]  |   |
|   |   | a-PLA   |  | A-Clas  |   |   |  | Risk Ratio  |  | Risk Ratio   |   |
| Study or Subgroup   | Event   |   | al Eve<br>0  | 38  | <u>Total</u><br>41  | 10.9  |  | Random, 95% Cl<br>1.00 [0.88, 1.13]   |  | M-H, Random, 95% Cl  |   |
| Andrews 2009  |   |   | 9  | 39  | 41  | 11.7  |  | 0.92 [0.83, 1.02]   |  |  |   |
| Jalvin 2007   |   | 7 2   |  | 19  | 20  | 7.4   |  | 0.89 [0.73, 1.10]   |  |  |   |
| arabiyik 2012   |   | 5 1   |  | 12  | 15  | 5.5   |  | 1.24 [0.94, 1.63]   |  |  |   |
| (aya 2008<br>Jam 2007   |   | 2 3   |  | 20  | 30  | 4.2   |  | 1.10 [0.79, 1.53]   |  |  |   |
| Vam 2007<br>Peker 2015  |   | 9 1<br>4 1  |  | 19  | 19<br>15  | 12.0  |  | 1.00 [0.91, 1.10]<br>1.17 [0.88, 1.55]  |  |  |   |
| Ratajczyk 2013  |   | 7 3   |  | 24  | 30  | 7.2   |  | 1.13 [0.91, 1.39]   |  | +  |   |
| Schebesta 2010  | 2   | 3 3   | 0  | 27  | 30  | 6.7   | %  | 0.85 [0.68, 1.07]   |  |  |   |
| Strydom 2008  |   | 5 2   |  | 21  | 25  | 4.7   |  | 0.89 [0.66, 1.21]   |  |  |   |
| Furan 2006<br>/an 2012  |   | 9 3<br>3 3  |  | 17  | 30  | 4.4   |  | 1.71 [1.24, 2.35]<br>0.95 [0.86, 1.04]  |  | and the second sec |   |
| aghoobi 2015  |   | 5 3   |  | 28  | 31<br>36  | 8.1   |  | 1.22 [1.00, 1.47]   |  |  |   |
| otal (95% CI)   |   | 37  | 0  |   | 362   | 100.0   | 1%   | 1.03 [0.95, 1.12]   |  | +  |   |
| Total events  | 33  |   |  | 307   |   |   |  | and the second second   |  |  |   |
| Heterogeneity: Tau <sup>=</sup><br>Fest for overall effect  |   |   |  | = 121   | P = 0   | 002); P   | -= 02%   | 1   | 0.1  | 0.2 0.5 1 2 5  | 1 |
| sociol overall ellec  |   | 20-0  |  |   |   |   |  |   |  | Favours [Cobra-PLA] Favours [LMA-Classic]  |   |
|   |   |   | 0000   |   |   |   |  |   |  |  |   |
|   | Cobra   |   |  | -Class  |   |   |  | k Ratio   |  | Risk Ratio   |   |
|   |   | s Total   | Ever   |   | otal  |   | M-H, F   | ixed, 95% Cl Year   |  |  |   |
|   |   | s Total   | Ever   |   |   | Weight<br>59.2%   | M-H, F   |   | i  | Risk Ratio   |   |
| \gah 2006   | Events<br>70  | <mark>s Total</mark><br>D 100   | <u>Even</u> )  | n <u>ts 1</u><br>60   | <b>otal</b><br>100  | 59.2%   | <u>M-H, F</u>  | <mark>ixed, 95% Cl Year</mark><br>7 [0.95, 1.43] 2006   |  | Risk Ratio   |   |
| Agah 2006<br>Strydom 2008   | Events<br>7(<br>14  | s Total<br>D 100<br>4 20  | <u>  Ever</u><br>)<br>)  | n <u>ts 1</u><br>60<br>20   | otal<br>100<br>25   | 59.2%<br>17.6%  | <b>M-H, F</b><br>1.1<br>0 0.8  | <b>ixed, 95% Cl Year</b><br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008  |  | Risk Ratio   |   |
| Agah 2006<br>Strydom 2008   | Events<br>70  | s Total<br>D 100<br>4 20  | <u>  Ever</u><br>)<br>)  | n <u>ts 1</u><br>60   | <b>otal</b><br>100  | 59.2%   | <b>M-H, F</b><br>1.1<br>0 0.8  | <mark>ixed, 95% Cl Year</mark><br>7 [0.95, 1.43] 2006   |  | Risk Ratio   |   |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012   | Events<br>7(<br>14  | s Total<br>0 100<br>4 20<br>5 15  | <u>  Ever</u><br>)<br>;  | n <u>ts 1</u><br>60<br>20   | otal<br>100<br>25   | 59.2%<br>17.6%  | <b>M-H, F</b><br>1.1<br>0.8<br>1.0   | <b>ixed, 95% Cl Year</b><br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008  |  | Risk Ratio   |   |
| <u>Study or Subgroup</u><br>Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Total (95% CI)   | Events<br>7(<br>14<br>15  | <u>s Total</u><br>0 100<br>4 20<br>5 15<br>0 15   | <u>  Ever</u><br> <br> <br>  | n <u>ts 1</u><br>60<br>20<br>15   | iotal<br>100<br>25<br>15<br>15  | 59.2%<br>17.6%<br>15.3%<br>7.9%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | ixed, 95% Cl         Year           7 [0.95, 1.43]         2006           8 [0.62, 1.24]         2008           0 [0.88, 1.13]         2012           5 [0.69, 2.26]         2015   |  | Risk Ratio   |   |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Total (95% CI)   | Events<br>7(<br>14<br>15<br>10  | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150   | <u>Ever</u> )<br>)<br>;  | n <u>ts 1</u><br>60<br>20<br>15<br>8  | iotal<br>100<br>25<br>15<br>15  | 59.2%<br>17.6%<br>15.3%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | <mark>ixed, 95% Cl Year</mark><br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012   |  | Risk Ratio   |   |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>F <b>otal (95% CI)</b><br>Fotal events   | Events<br>7(<br>14<br>10<br>10  | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9  | I Ever<br>)<br>;<br>;<br>1   | n <u>ts 1</u><br>60<br>20<br>15<br>8<br>03  | Total<br>100<br>25<br>15<br>15<br>15  | 59.2%<br>17.6%<br>15.3%<br>7.9%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | ixed, 95% Cl         Year           7 [0.95, 1.43]         2006           8 [0.62, 1.24]         2008           0 [0.88, 1.13]         2012           5 [0.69, 2.26]         2015   |  | Risk Ratio   |   |
| kgah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>To <b>tal (95% CI)</b><br>Total events<br>Heterogeneity: Chi <sup>≈</sup> =  | Events<br>7(<br>14<br>10<br>10<br>10<br>5<br>5<br>4.27, df  | s Total<br>D 100<br>4 20<br>5 15<br>D 15<br><b>150</b><br>9<br><sup>2</sup> = 3 (P =  | <u>Ever</u> )<br>)<br>;<br>1<br>: 0.23);   | n <u>ts 1</u><br>60<br>20<br>15<br>8<br>03  | Total<br>100<br>25<br>15<br>15<br>15  | 59.2%<br>17.6%<br>15.3%<br>7.9%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015   | H  | Risk Ratio<br>M-H, Fixed, 95% Cl   | 1 |
| kgah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>To <b>tal (95% CI)</b><br>Total events<br>Heterogeneity: Chi <sup>≈</sup> =  | Events<br>7(<br>14<br>10<br>10<br>10<br>5<br>5<br>4.27, df  | s Total<br>D 100<br>4 20<br>5 15<br>D 15<br><b>150</b><br>9<br><sup>2</sup> = 3 (P =  | <u>Ever</u> )<br>)<br>;<br>1<br>: 0.23);   | n <u>ts 1</u><br>60<br>20<br>15<br>8<br>03  | Total<br>100<br>25<br>15<br>15<br>15  | 59.2%<br>17.6%<br>15.3%<br>7.9%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015   | 0.1  | Risk Ratio   | 1 |
| kgah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>To <b>tal (95% CI)</b><br>Total events<br>Heterogeneity: Chi <sup>≈</sup> =  | Events<br>7(<br>14<br>10<br>10<br>: 4.27, df<br>: Z = 1.23  | s Total<br>D 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br><sup>1</sup> = 3 (P =<br>3 (P = 0.1)  | <u>Even</u> )<br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | n <u>ts 1</u><br>60<br>20<br>15<br>8<br>03<br>I <sup>≠</sup> = 30   | Total<br>100<br>25<br>15<br>15<br>155   | 59.2%<br>17.6%<br>15.3%<br>7.9%   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]   | L0.1   | Risk Ratio<br>M-H, Fixed, 95% Cl   | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>æ</sup> =<br>Test for overall effect   | Events<br>7(<br>14<br>15<br>10<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20          | s Total<br>D 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>'= 3 (P =<br>3 (P = 0.)<br>bra-PLA  | <u>Even</u> )<br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | nts 1<br>60<br>20<br>15<br>8<br>03<br>  <sup>2</sup> = 30   | otal<br>100<br>25<br>15<br>15<br>155  | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%   | t M-H, F<br>1.1<br>0.8<br>1.0<br>1.2<br>1.1<br>1.1   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference  |  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>≈</sup> =<br>Test for overall effect   | Events<br>7(<br>14<br>15<br>10<br>5<br>5<br>4.27, df<br>5<br>7<br>2 = 1.23<br>Cot<br>Mean                             | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>8<br>5<br>3 (P = 0.1<br>5<br>3 (P = 0.1<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5<br>5   | <u>Even</u><br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | nts 1<br>60<br>20<br>15<br>8<br>03<br>I <sup>2</sup> = 30<br>LMA<br><u>Mean</u>   | otal<br>100<br>25<br>15<br>15<br>155<br>155   | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%   | t M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>Weight   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV, Random, 95% C   | 1  | Risk Ratio<br>M-H, Fixed, 95% Cl   | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>#</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Andrews 2009  | Events<br>7(<br>14<br>10<br>10<br>24.27, df<br>2 = 1.23<br>Col<br>Mean<br>39  | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>5 3 (P = 0.1<br>5 3 (P = 0.1<br>5 5 0<br>5 3 (P = 0.1<br>5 5 0<br>5 1 | <u>Ever</u><br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | nts 1<br>60<br>20<br>15<br>8<br>03<br>I <sup>2</sup> = 30<br>LMA<br><u>Mean</u><br>27   | otal           100           25           15           15           155           155           100           100           25           15           155           100           100           100           | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br><u>Total</u><br>40  | t M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0<br>1.1<br>Weight<br>9.8%   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65   | 1  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>#</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Marews 2009<br>∋alvin 2007  | Events<br>7(<br>14<br>10<br>10<br>24.27, df<br>22 = 1.23<br>Col<br>Mean<br>39<br>11.6                                 | s Total<br>D 100<br>4 20<br>5 15<br>0 15<br>150<br>3<br>(P = 0.:<br>5<br>0<br>21<br>5.9   | <u>Ever</u><br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | t <u>s 1</u><br>60<br>20<br>15<br>8<br>03<br>  <sup>2</sup> = 30<br><b>LMA</b><br><u>Mean</u><br>27<br>10.3   | 'otal           100           25           15           15           155           '%           -Class           SD           10           3.5  | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br>Total<br>40<br>20   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0<br>1.1<br>0<br>1.1<br>0<br>1.1<br>0<br>1.3<br>1.1<br>0<br>1.3<br>1.1<br>0.8<br>1.0<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31  | 1<br>]<br>]  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>#</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Stalvin 2007<br>Caya 2008   | Events<br>7(<br>14<br>10<br>10<br>24.27, df<br>2 = 1.23<br>Col<br>Mean<br>39  | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>5 3 (P = 0.1<br>5 3 (P = 0.1<br>5 5 0<br>5 3 (P = 0.1<br>5 5 0<br>5 1 2 1<br>5 1 2 1 2 1 2 1<br>5 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1   | <u>Ever</u><br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | nts 1<br>60<br>20<br>15<br>8<br>03<br>I <sup>2</sup> = 30<br>LMA<br><u>Mean</u><br>27   | otal           100           25           15           15           155           155           100           100           25           15           155           100           100           100           | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br>Total<br>40<br>20   | t M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0<br>1.1<br>Weight<br>9.8%   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31  | 1<br>]<br>]  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>#</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Stalvin 2007<br>Caya 2008   | Events<br>7(<br>14<br>10<br>10<br>24.27, df<br>22 = 1.23<br>Col<br>Mean<br>39<br>11.6                                 | s Total<br>D 100<br>4 20<br>5 15<br>0 15<br>150<br>3<br>(P = 0.:<br>5<br>0<br>21<br>5.9   | <u>Ever</u><br>)<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;<br>;   | t <u>s 1</u><br>60<br>20<br>15<br>8<br>03<br>  <sup>≠</sup> = 30<br><b>LMA</b><br><u>Mean</u><br>27<br>10.3<br>19   | 'otal           100           25           15           15           155           '%           -Class           SD           10           3.5  | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br>Total<br>40<br>20   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0<br>1.1<br>0<br>1.1<br>0<br>1.1<br>0<br>1.3<br>1.1<br>0<br>1.3<br>1.1<br>0.8<br>1.0<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-6.83, 4.83  | 1<br>]<br>]<br>]   | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Fotal (95% CI)<br>Fotal events<br>Heterogeneity: Chi <sup>#</sup> =<br>Fest for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Balvin 2007<br>Kaya 2008<br>Peker 2015  | Events<br>7(<br>14<br>10<br>10<br>24.27, df<br>:Z = 1.23<br>Col<br>Mean<br>39<br>11.6<br>18                           | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>5 3 (P = 0.1<br>5 9<br>21<br>5.9<br>12  | <u>Ever</u><br>1<br>5<br>6<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>3<br>0<br>3<br>0   | t <u>s 1</u><br>60<br>20<br>15<br>8<br>03<br>  <sup>≠</sup> = 30<br><b>LMA</b><br><u>Mean</u><br>27<br>10.3<br>19   | otal           100           25           15           15           155           155           100           25           100           25           100           3.5           11                          | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br>Total<br>40<br>20<br>30   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>0.1<br>1.1<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0.8<br>0   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>1 2.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47  | 1<br>]<br>]<br>]<br>] –  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>#</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Study or Subgroup | Events<br>7(<br>14<br>10<br>10<br>2<br>2 = 1.23<br>Col<br>Mean<br>39<br>11.6<br>18<br>19.1<br>15                      | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>3<br>i= 3 (P = 0.1<br>5<br>0<br>12<br>14.7<br>4  | I Ever<br>1<br>5<br>6<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7   | tts 1<br>60<br>20<br>15<br>8<br>03<br>1 <sup>2</sup> = 30<br><b>LMAA</b><br>27<br>10.3<br>19<br>24.4<br>16  | otal           100           25           15           15           155           155           100           .cClass           SD           100           3.5           11           20.5           6        | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br><u>Total</u><br>20<br>20<br>30<br>15<br>30  | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br><b>Weight</b><br>9.8%<br>18.1%<br>11.3%<br>19.2%   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-6.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-3.58, 1.58   | 1<br>]<br>]<br>]<br>] —  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Total (95% CI)<br>Total events<br>Heterogeneity: Chi <sup>22</sup> =<br>Test for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Palvin 2007<br>Caya 2008<br>Peker 2015<br>Schebesta 2010<br>Turan 2006   | Events<br>7(<br>14<br>19<br>10<br>10<br>24.27, df<br>27 = 1.23<br>Cot<br>Mean<br>39<br>11.6<br>18<br>19.1<br>15<br>21 | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>'= 3 (P = 0.<br>3 (P = 0.<br>12<br>12<br>14.7<br>4<br>12  | 1 Ever<br>1<br>5<br>5<br>1<br>5<br>1<br>5<br>1<br>5<br>1<br>5<br>1<br>5<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2<br>2   | its         1           60         20           15         8           03          ² = 30           LIMA         27           10.3         19           24.4         16           20         24.4 | otal           100           25           15           15           155           155           %           100           3.5           11           20.5           6           11                            | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br>Total<br>40<br>20<br>30<br>15<br>30<br>30   | M-H, F<br>1.1<br>0.8<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.2<br>1.1<br>Weight<br>9.8%<br>18.1%<br>13.8%<br>19.2%<br>11.3%  | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-3.58, 1.58<br>1.00 [-4.83, 6.83  | 1<br>]<br>]<br>] —<br>] —  | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Carabiyik 2012<br>Peker 2015<br>Fotal (95% CI)<br>Fotal events<br>Heterogeneity: Chi <sup>2</sup> =<br>Fest for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Salvin 2007<br>Caya 2008<br>Peker 2015<br>Schebesta 2010<br>Furan 2006<br>Van 2012  | Events<br>7(<br>14<br>10<br>10<br>2<br>2 = 1.23<br>Col<br>Mean<br>39<br>11.6<br>18<br>19.1<br>15                      | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>9<br>3 (P = 0<br>0 21<br>5.9<br>127<br>14.7<br>12<br>10   | I Ever<br>1<br>5<br>6<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7<br>7   | tts 1<br>60<br>20<br>15<br>8<br>03<br>  <sup>2</sup> = 30<br>LMAA<br>27<br>10.3<br>19<br>24.4<br>16<br>20<br>22<br>24   | otal           100           25           15           15           155           155           100           .cClass           SD           100           3.5           11           20.5           6        | 59.2%<br>17.6%<br>15.3%<br>7.9%<br>100.0%<br>sic<br><u>Total</u><br>20<br>20<br>30<br>15<br>30  | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br><b>Weight</b><br>9.8%<br>18.1%<br>11.3%<br>19.2%   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>0 [0.95, 1.27]<br>Mean Difference<br>12.00 [5.36, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-8.83, 6.83<br>5.00 [0.87, 9.13  | 1<br>]<br>]<br>]<br>] —<br>]                                       | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Fotal (95% CI)<br>Fotal events<br>Heterogeneity: Chi <sup>#</sup> =<br>Fest for overall effect<br>Study or Subgroup<br>Modrews 2009<br>Dalvin 2007<br>Kaya 2008<br>Peker 2015<br>Schebesta 2010<br>Furan 2006<br>Van 2012<br>Yaghoobi 2015   | Events<br>7(<br>14<br>19<br>10<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20          | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>9<br>3 (P = 0<br>0 21<br>5.9<br>127<br>14.7<br>12<br>10   | I         Ever           I         I | tts 1<br>60<br>20<br>15<br>8<br>03<br>  <sup>2</sup> = 30<br>LMAA<br>27<br>10.3<br>19<br>24.4<br>16<br>20<br>22<br>24   | otal           100           25           15           15           155           %           •Class           SD           10           3.5           11           20.5           6           11           7 | 59.2%<br>17.6%<br>15.3%<br>7.9%<br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b>  | <ul> <li>M-H, F</li> <li>1.1</li> <li>0.8</li> <li>1.0</li> <li>1.2</li> <li>1.10</li> <li>1.2</li> <li>1.10</li> <li>1.2</li> <li>1.10</li> <li>1.2</li> <li>1.10</li> <li>1.2</li> <li>1.11</li> <li>1.2%</li> </ul>   | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>D [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-3.58, 1.58<br>1.00 [-4.83, 6.83<br>5.00 [0.87, 9.13<br>2.94 [-2.92, 8.80 | 1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1 | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Fotal (95% CI)<br>Fotal events<br>Heterogeneity: Chi <sup>#</sup> =<br>Fest for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Balvin 2007<br>Kaya 2008<br>Peker 2015<br>Schebesta 2010<br>Furan 2008<br>Van 2012<br>Vaghoobi 2015<br>Fotal (95% CI)   | Events<br>7(<br>14<br>19<br>109<br>24.27, df<br>27<br>29.94   | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>= 3 (P = 0.1<br>5.9<br>12<br>14.7<br>4<br>12<br>10<br>16.35   | I         Ever           I         I | tts 1<br>60<br>20<br>15<br>8<br>8<br>03<br>I <sup>*</sup> = 30<br>103<br>19<br>24.4<br>16<br>20<br>22<br>27   | otal<br>100<br>25<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15   | 59.2%<br>17.6%<br>17.6%<br>15.3%<br>7.9%<br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b></b> | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.1<br>0.8<br>1.0<br>0.8<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.3<br>%<br>11.3%<br>11.3%<br>11.3%<br>11.3%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>1. | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>D [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-3.58, 1.58<br>1.00 [-4.83, 6.83<br>5.00 [0.87, 9.13<br>2.94 [-2.92, 8.80 | 1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1 | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |
| Agah 2006<br>Strydom 2008<br>Karabiyik 2012<br>Peker 2015<br>Fotal (95% CI)<br>Fotal events<br>Heterogeneity: Chi <sup>≈</sup> =<br>Fest for overall effect<br>Study or Subgroup<br>Andrews 2009<br>Salvin 2007<br>Kaya 2008<br>Peker 2015<br>Schebesta 2010<br>Furan 2006<br>Van 2012  | Events<br>7(<br>14<br>19<br>109<br>24.27, df<br>27<br>29.94   | s Total<br>0 100<br>4 20<br>5 15<br>0 15<br>150<br>9<br>= 3 (P = 0.1<br>5.9<br>12<br>14.7<br>4<br>12<br>10<br>16.35   | I         Ever           I         I | tts 1<br>60<br>20<br>15<br>8<br>8<br>03<br>I <sup>*</sup> = 30<br>103<br>19<br>24.4<br>16<br>20<br>22<br>27   | otal<br>100<br>25<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15<br>15   | 59.2%<br>17.6%<br>17.6%<br>15.3%<br>7.9%<br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b>100.0%</b><br><b></b> | M-H, F<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>1.0<br>1.2<br>1.1<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.0<br>0.8<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.2<br>1.1<br>0.8<br>1.3<br>1.3<br>1.3<br>1.3<br>1.1.3%<br>11.3%<br>11.3%<br>11.3%<br>11.3%<br>11.3%<br>11.3%<br>11.3%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.2%<br>11.         | ixed, 95% Cl Year<br>7 [0.95, 1.43] 2006<br>8 [0.62, 1.24] 2008<br>0 [0.88, 1.13] 2012<br>5 [0.69, 2.26] 2015<br>D [0.95, 1.27]<br>Mean Difference<br>IV. Random, 95% C<br>12.00 [5.35, 18.65<br>1.30 [-1.71, 4.31<br>-1.00 [-8.83, 4.83<br>-5.30 [-18.07, 7.47<br>-1.00 [-3.58, 1.58<br>1.00 [-4.83, 6.83<br>5.00 [0.87, 9.13<br>2.94 [-2.92, 8.80 | 1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1<br>1 | Risk Ratio<br>M-H, Fixed, 95% CI<br>0.2 0.5 1 2 5<br>Favours [Cobra-PLA] Favours [LMA-Classic]<br>Mean Difference  | 1 |

Figure 2. Forest plot for comparison of Cobra-PLA and LMA-Classic for OLP (cmH2O); insertion success rate at the first attempt; ease of insertion; and insertion time (s). CI = confidence interval, Cobra-PLA = Perilaryngeal Airway, I<sup>2</sup>=I-square heterogeneity statistic, IV = inverse variance, LMA = Laryngeal Mask Airway, OLP = Oropharyngeal leak pressure.

pressure ventilation and is determined by the strength of the seal between the cuff of the mask and the surrounding soft tissue of the neck.  $^{[4,28]}$ 


Several studies showed that LMA-Classic can provide safe and effective airway management.<sup>[29,30]</sup> However, certain limitations were found in this reusable device, especially its low-pressure seal, which may be insufficient for positive pressure ventilation.<sup>[31]</sup>


Gastric distention with a risk of regurgitation may be caused by leaks in certain cases.<sup>[31]</sup> In the present meta-analysis, we found significantly higher OLP with Cobra-PLA than LMA-Classic. The higher OLP in the Cobra-PLA group compared with those of other groups may be due to the larger cuff structure compared with those of the other devices. Increased OLP offers particular advantage in obese patients, lithotomy position, restrictive lung

| Table 3     |                     |                |                  |
|-------------|---------------------|----------------|------------------|
| Subgroup me | ta-analysis for OLP | with Cobra-PLA | and LMA-Classic. |

|                        | Subgroup             | References      | P value | MD   | 95% CI       | I-square; P value |
|------------------------|----------------------|-----------------|---------|------|--------------|-------------------|
| Age                    | children             | [2,11]          | .05     | 2.26 | (-0.02,4.74) | 0%; .77           |
| 0                      | adults               | [3,8-10,6,31]   | <.00001 | 3.90 | (1.56,6.23)  | 91%; .001         |
| NMB                    | No                   | [6,3,8,2,11,31] | <.00001 | 3.92 | (2.77,5.07)  | 0%; .74           |
|                        | Yes                  | [10,9]          | .31     | 2.95 | (-2.74,8.63) | 98%; <.00001      |
| Laparoscopic surgery   | No                   | [2-3,8-11,31]   | .002    | 3.41 | (1.25,5.57)  | 90%; <.00001      |
|                        | Yes                  | [6]             | .01     | 5.20 | (1.13,9.27)  | NA                |
| OLP measurement method | Audible noise        | [2-3,8,10-11,6] | .004    | 2.70 | (0.86,4.54)  | 65%; .004         |
|                        | oral capnography     | [31]            | <.00001 | 5.00 | (2.59,7.41)  | NA                |
|                        | Manometric stability | [9]             | <.00001 | 5.80 | (5.36,6.24)  | NA                |

CI = confidence interval, MD = mean difference, NA = not applicable.








Figure 4. Forest plot for comparison of Cobra-PLA and LMA-Classic for blood staining; sore throat; and dysphagia. CI=confidence interval, Cobra-PLA= Perilaryngeal Airway, I<sup>2</sup>=I-square heterogeneity statistic, IV=inverse variance, LMA=Laryngeal Mask Airway.

diseases, and pneumo-peritoneum patients.<sup>[32]</sup> Thus, Cobra-PLA may be considered as an alternative to LMA-Classic during general anesthesia.

Other factors that may affect OLP include age, the use of NBM, intra-abdominal pressure during surgery, measurement method, and LMA size selection criteria.<sup>[33]</sup> In our metaanalysis, substantial overall heterogeneity ( $I^2=88\%$ ) was reduced by subgroup analysis based on pediatric patients  $(I^2=0\%)$  and non-use of NMB  $(I^2=0\%)$ . A polled data of 8 trials, which did not use NMB, showed similar device insertion time between Cobra-PLA and LMA-Classic. Furthermore, the high heterogeneity  $(I^2=61\%)$  of insertion time was possibly relative to the measurement standards among the studies included in our analysis.

# Table 4

|                        | Subgroup             | References    | P value | MD   | 95% CI       | I-square; P value |
|------------------------|----------------------|---------------|---------|------|--------------|-------------------|
| age                    | children             | [2,19,20]     | .03     | 2.79 | (0.25, 5.34) | 89%; <.00001      |
|                        | adults               | [18,35,36]    | .0005   | 7.85 | (3.44,12.26) | 90%; <.00001      |
| NMB                    | No                   | [2,18,19,35]  | .004    | 3.05 | (0.95,5.16)  | 85%; <.00001      |
|                        | Yes                  | [20,36]       | .006    | 9.45 | (2.76,16.14) | 93%; <.00001      |
| OLP measurement method | Audible noise        | [2,20]        | .24     | 3.42 | (-2.32,9.16) | 90%; .001         |
|                        | Manometric stability | [18,19,35,36] | .001    | 4.73 | (1.90,7.56)  | 92%; <.00001      |

CI = confidence interval, MD = mean difference, NA = not applicable.




Figure 5. Forest plot for comparison of Cobra-PLA and LMA-Unique for OLP (cmH2O); insertion success rate at the first attempt; ease of insertion; and insertion time (s).CI = confidence interval, Cobra-PLA = Perilaryngeal Airway, I<sup>2</sup>=I-square heterogeneity statistic, IV = inverse variance, LMA = Laryngeal Mask Airway.

LMA-Unique is the 1-off version of the LMA-Classic and is currently used for both adult and pediatric patients.<sup>[23]</sup> We also found a significantly higher OLP with Cobra-PLA compared with LMA-Unique. The difference in OLP between the 2 groups may be due to the different structure designs.<sup>[23]</sup> A bowl-shaped cuff of LMA-Unique surrounding the larynx decides the sealing mechanism. The device may tilt to 1 side or the other owing to the posterior placement of the exiting breathing tube from the center of the posterior wall. However, Cobra-PLA can provide evident stability with its wide and flat distal head, which is sufficiently rigid to prevent movement of the device.<sup>[34,35]</sup>

Evident data heterogeneity in the combined OLP result is one limitation in our finding. High heterogeneity ( $I^2 = 91\%$ ) cannot be decreased despite the use of various subgroup analyses. This finding is probably due to the use of different size of devices in the trials. In 1 trial, <sup>[23]</sup> sizes 1.5, 2, and 3 of Cobra-PLA and sizes 1.5,




Figure 6. Forest plot for comparison of Cobra-PLA and LMA-Unique for blood staining; laryngospasm; and sore throat. CI=confidence interval, Cobra-PLA= Perilaryngeal Airway, I<sup>2</sup>=I-square heterogeneity statistic, IV=inverse variance, LMA=Laryngeal Mask Airway.

2, and 2.5 of LMA-Unique were compared; 1 trial<sup>[2]</sup> compared sizes 0.5, 1, 1.5, 2, and 3 of Cobra-PLA and size 1.5, 2, 2.5, 3, 4, and 5 of LMA-Unique; and another study<sup>[22]</sup> compared sizes 0.5, 1, 1.5, and 2 of Cobra-PLA and sizes 1, 1.5, 2, and 2.5 of LMA-Unique. Notably, larger-sized (1.5, 2) Cobra-PLA possesses the dorsal cuff, which may provide higher OLP than the smaller variants (0.5, 1). In addition, a study comparing Cobra-PLA and LMA-Unique in adult patients found that the former presented higher OLP.<sup>[21]</sup> The ease of insertion was the same for 2 devices with high heterogeneity ( $I^2 = 87\%$ ). Considering that only 2 trials were included in the analysis, further studies are required to validate the conclusion.

Compared with the Xu' meta-analysis,<sup>[36]</sup> our study presented different findings. First, 5 eligible RCTs<sup>[2,10,12,17,24]</sup> were not included in the Xu' study, and we included these RCTs in our study. Second, this work was the first study to show that Cobra-PLA can provide higher OLP than LMA-Classic regardless of age group (children or adults), surgical type (laparoscopic or non-laparoscopic), use of 3 OLP measurement methods, and lack of NMB. Third, Cobra-PLA also offers higher OLP than LMA-

Unique regardless of age group (children or adults), with or without NMB, and use of manometric stability of measurement method, Fourth, we also first find that Cobra-PLA did not exhibit higher OLP in comparison with LMA-Classic and LMA-Unique under conditions of NMB and audible noise measurement method. Lastly, significant heterogeneity ( $I^2=91\%$ ) was found when the studies were pooled to evaluate the OLP between Cobra-PLA and LMA-Classic in the Xu' meta-analysis, but the study didn't explore the possible causes of such heterogeneity. On the contrary, the heterogeneity seen in our study can be explained by the difference in age and the use of NMB between studies.

Several limitations were found in present work. First, in addition to high heterogeneity discussed above, differences in induction, maintenance, depth of anesthesia, and patient population studied may contribute to the evident data heterogeneity. Although we conducted subgroup and sensitivity analyses in an attempt to control several factors, we cannot account for all possible confounding factors. Second, we comprehensively searched the published studies, but potential publication bias may still exist due to failure to include ongoing or unpublished trials. Finally, several included studies were of poor quality. Two studies<sup>[16,19]</sup> did not blind the participants, and some included studies did not describe the details of binding the outcome assessment. Therefore, additional high-quality studies are required to certify our results.

In conclusion, our findings show that Cobra-PLA provides significantly higher OLP than both LMA-Classic and LMA-Unique and a similar clinical performance to both devices during general anesthesia.

#### **Author contributions**

Study design: Yuan T. Data collection and Wring the draft: Yuan T, Qin C, Feng C. Data interpretation, discussion and preparation of the final manuscript: Yuan T, Guangyou D, Hong L. All authors have read and approved the final manuscript.

#### References

- Brain AI. The development of the Laryngeal Mask a brief history of the invention, early clinical studies and experimental work from which the Laryngeal Mask evolved. Eur J Anaesthesiol Suppl 1991;4:5–17.
- [2] Van ZT, Brimacombe J. Comparison of cuff-pressure changes in silicone and PVC laryngeal masks during nitrous oxide anaesthesia in spontaneously breathing children. Anaesthesiol Intensive Ther 2012; 44:63–70.
- [3] Andrews DT, Williams DL, Alexander KD, et al. Randomised comparison of the Classic Laryngeal Mask Airway (TM) with the Cobra Perilaryngeal Airway (TM) during anaesthesia in spontaneously breathing adult patients. Anaesth Intens Care 2009;37:85–92.
- [4] Keller C, Brimacombe JR, Keller K, et al. Comparison of four methods for assessing airway sealing pressure with the laryngeal mask airway in adult patients. Anesth Analg 1998;87:1379–82.
- [5] Lopez-Gil M, Brimacombe J, Keller C. A comparison of four methods for assessing oropharyngeal leak pressure with the laryngeal mask airway (LMA) in paediatric patients. Pediatr Anesth 2001;11: 319–21.
- [6] Galvin EM, van Doorn M, Blazquez J, et al. A randomized prospective study comparing the Cobra Perilaryngeal Airway and Laryngeal Mask Airway-Classic during controlled ventilation for gynecological laparoscopy. Anesth Analg 2007;104:102–5.
- [7] Schebesta K, Lorenz V, Schebesta EM, et al. Exposure to anaesthetic trace gases during general anaesthesia: CobraPLA vs. LMA classic. Acta Anaesthesiolog Scandinavica 2010;54:848–54.
- [8] Yaghoobi S, Abootorabi SM, Kayalha H, et al. Efficacy of the new perilaryngeal airway (CobraPLA<sup>TM</sup>) versus the laryngeal mask airway (LMA<sup>TM</sup>) to improve oropharyngeal leak pressure in obese and overweight patients. Tanaffos 2015;14:42–8.
- [9] Khazin V, Ezri T, Yishai R, et al. Gastroesophageal regurgitation during anesthesia and controlled ventilation with six airway devices. J Clin Anesth 2008;20:508–13.
- [10] Peker G, Takmaz SA, Baltacı B, et al. Comparison of four different supraglottic airway devices in terms of efficacy, intra-ocular pressure and haemodynamic parameters in children undergoing ophthalmic surgery. Turk J Anaesthesiol Reanimation 2015;43:304–12.
- [11] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:1–28.
- [12] Agah M, Yahyavi P, Roudneshin F. Comparison between classic laryngeal mask and cobra perilaryngeal airway during mechanical ventilation. Tanaffos 2006;5:13–9.
- [13] Strydom CS, Le Roux PJ. A clinical comparison of disposable airway devices. Southern African J Anaesth Analg 2008;14:31–6.
- [14] Ratajczyk P, Małachowska B, Gaszyńska E, et al. A randomised comparison between Cobra PLA and classic laryngeal mask airway and

laryngeal tube during mechanical ventilation for general anaesthesia. Anaesthesiol Intensive Ther 2013;45:20-4.

- [15] Karabiyik L, Emmez G, ÖNCÜL S. The effects of the Cobra perilaryngeal airway on intraocular pressure. Turkish J Med Sci 2012;42:667–73.
- [16] Akça O, Wadhwa A, Sengupta P, et al. The new perilaryngeal airway (CobraPLA<sup>TM</sup>) is as efficient as the laryngeal mask airway (LMA<sup>TM</sup>), but provides better airway sealing pressures. Anesth Analg 2004;99:272–8.
- [17] Nam SB, Han DW, Chang CH, et al. A randomised, crossover comparison between the CobraPLA<sup>®</sup> and the LMA Classic<sup>TM</sup> in paralysed patients. Anaesthesia 2007;62:1285–8.
- [18] Turan A, Kaya G, Koyuncu O, et al. Comparison of the laryngeal mask (LMA<sup>TM</sup>) and laryngeal tube (LT<sup>®</sup>) with the new perilaryngeal airway (CobraPLA<sup>®</sup>) in short surgical procedures. Eur J Anaesthesiol 2006; 23:234–8.
- [19] Kaya G, Koyuncu O, Turan N, et al. Comparison of the laryngeal mask (LMA (TM)) and laryngeal tube (LT<sup>®</sup>) with the perilaryngeal airway (CobraPLA<sup>®</sup>) in brief paediatric surgical procedures. Anaesth Intensive Care 2008;36:425–9.
- [20] Van Zundert A, Brimacombe J, Kamphuis R, et al. The anatomical position of three extraglottic airway devices in patients with clear airways. Anaesthesia 2006;61:891–5.
- [21] Gaitini L, Yanovski B, Somri M, et al. A comparison between the PLA Cobra<sup>TM</sup> and the Laryngeal Mask Airway Unique<sup>TM</sup> during spontaneous ventilation: a randomized prospective study. Anesth Analg 2006; 102:631–6.
- [22] Szmuk P, Ghelber O, Matuszczak M, et al. A prospective, randomized comparison of cobra perilaryngeal airway and laryngeal mask airway unique in pediatric patients. Anesth Analg 2008;107:1523–30.
- [23] Gaitini L, Carmi N, Yanovski B, et al. Comparison of the CobraPLA<sup>TM</sup> (Cobra Perilaryngeal Airway) and the Laryngeal Mask Airway Unique<sup>TM</sup> in children under pressure controlled ventilation. Pediatr Anesth 2008;18:313–9.
- [24] Schebesta K, Karanovic G, Krafft P, et al. Distance from the glottis to the grille: the LMA Unique, Air-Q and CobraPLA as intubation conduits: a randomised trial. Eur J Anaesthesiol (EJA) 2014;31:159–65.
- [25] Andre van Zundert MD, Al-Shaikh B, Brimacombe J, et al. Comparison of three disposable extraglottic airway devices in spontaneously breathing adults. Anesthesiology 2006;104:1165–9.
- [26] Gaitini LA, Somri MJ, Kersh K, et al. A comparision of the Laryngeal mask airway unique<sup>TM</sup>, pharyngeal airway X press<sup>TM</sup> and perilaryngeal airway cobra<sup>TM</sup> in paralyzed anesthetized adult patients. Anesthesiology 2003;99:1495.
- [27] Beleña JM, Núñez M, Anta D, et al. Comparison of laryngeal mask airway supreme and laryngeal mask airway proseal with respect to oropharyngeal leak pressure during laparoscopic cholecystectomy: a randomised controlled trial. Eur J Anaesthesiol (EJA) 2013;30: 119–23.
- [28] Seet E, Rajeev S, Firoz T, et al. Safety and efficacy of laryngeal mask airway Supreme versus laryngeal mask airway ProSeal: a randomized controlled trial. Eur J Anaesthesiol (EJA) 2010;27:602–7.
- [29] Lopez-Gil M, Brimacombe J, Alvarez M. Safety and efficacy of the laryngeal mask airway A prospective survey of 1400 children. Anaesthesia 1996;51:969–72.
- [30] Mason DG, Bingham RM. The laryngeal mask airway in children. Anaesthesia 1990;45:760–3.
- [31] Gursoy F, Algren JT, Skjonsby BS. Positive pressure ventilation with the laryngeal mask airway in children. Anesth Analg 1996;82:33–8.
- [32] Lopez-Gil M, Brimacombe J. The ProSealTM laryngeal mask airway in children. Pediatr Anesth 2005;15:229–34.
- [33] Shimbori H, Ono K, Miwa T, et al. Comparison of the LMA-ProSeal<sup>TM</sup> and LMA-Classic<sup>TM</sup> in children. Br J Anaesth 2004;93:528–31.
- [34] Szmuk P, Ezri T, Narwani A, et al. Use of Cobra-PLA as a conduit for fiberoptic intubation in a child with neck instability. Pediatr Anesth 2006;16:217–8.
- [35] Szmuk P, Matuszczeak M, Carlson RF, et al. Use of CobraPLATM for airway management in a neonate with Desbuquois syndrome. Case report and anesthetic implications. Pediatr Anesth 2005;15:602–5.
- [36] Xu R, Zhu Y, Fan Q, et al. Comparison between the cobra perilaryngeal airway and laryngeal mask airways under general anesthesia: a systematic review and meta-analysis. Anesth Analg 2017;125:1–9.